Background
==========

*Escherichia coli*is the predominant cause of both community and nosocomial urinary tract infection (UTI). In the UK, trimethoprim or nitrofurantoin are usually recommended for empirical treatment of episodes of uncomplicated cystitis in the community \[[@B1]\], whilst parenteral cephalosporins and aminoglycosides are reserved for complicated infections or pyelonephritis. In North America a cut off point of 20% has been suggested as the level of resistance at which an agent should no longer be used empirically \[[@B2]\]. A UK study of the antimicrobial susceptibility of bacterial pathogens causing UTI in 1999 -- 2000 showed high levels of resistance to trimethoprim, amoxicillin and oral cephalosporins \[[@B3]\] whilst a study of three collections of *E. coli*strains obtained from patients in East London in 1991, 1999 and 2004 showed rates of trimethoprim resistance of over 30% \[[@B4]\]. The emergence of strains producing extended spectrum β-lactamases (ESBL\'s) and others exhibiting quinolone resistance now threatens the empirical use of both cephalosporins and ciprofloxacin \[[@B5]\] seriously limiting treatment regimens. In order to determine current levels of resistance to antibiotics commonly used locally for empirical treatment, we reviewed susceptibility to ampicillin, amoxicillin/clavaulanate, trimethoprim, nitrofurantoin, cefalexin, gentamicin, ciprofloxacin and cefpodoxime amongst all *E. coli*urinary isolates obtained in our laboratory over a 1 year period.

Methods
=======

All *E. coli*isolates recovered from urine samples submitted for microscopy, culture and sensitivity to the laboratories of Barts and The London NHS Trust between 1^st^January and 31^st^December 2005 were included. Samples originating from General practice, Accident and Emergency or other primary care destinations were considered representative of community isolates whilst samples originating from patients hospitalised for 48 hrs or more on general or specialised wards were considered nosocomial.

Primary isolation of strains from urine specimens was performed using chromogenic agar (Mast diagnostics, Bootle, Merseyside) and bacterial counts quantified by inoculation of 0.3 μl of urine onto cystine lactose electrolyte deficient (CLED) agar (Mast diagnostics). Sensitivity testing was performed by the BSAC disc diffusion method using ampicillin (25 μg), cefalexin (30 μg), gentamicin (10 μg), ciprofloxacin (1 μg), nitrofurantoin (200 μg), trimethoprim (2.5 μg), amoxicillin/clavulanate (30 μg) and cefpodoxime (10 μg) discs and isosensitest agar.

Multi-drug resistance was defined in this analysis as resistance to three or more of the following antibiotics: ciprofloxacin, cefpodoxime, amoxicillin/clavulanate and gentamicin.

Differences in the prevalence of antibiotic resistance between groups were analysed using the χ^2^test. Strength of association was assessed by calculation of odds ratios with 95% confidence intervals.

Results
=======

A total of 11,865 *E. coli*isolates were cultured from urine samples over the study period, of these 10,521 (88.7%) were considered community isolates while 1,344 (11.3%) were of nosocomial origin. 10,166 (85.7%) were from women and 1,656 (14.0%) from men (43 sex unknown). 1,227 (10.3%) were from children \< 16 years of age.

The frequency of antimicrobial susceptibility of all isolates to the eight antibiotics is shown in tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}. Nitrofurantoin was the most active agent (94% susceptible) followed by gentamicin (93.7%) and cefpodoxime (92%). Ampicillin and trimethoprim were the least active agents with 55% and 40% of isolates exhibiting resistance respectively.

###### 

Frequency of antibiotic susceptibility in relation to sex

  Antibiotic                Female (*n*= 10157)   Male (*n*= 1656)   *P*    OR (CI95%)             
  ------------------------- --------------------- ------------------ ------ ------------- -------- -------------------
  Ampicillin                10153                 5460 (53.8)        1652   1051 (63.6)   ≤0.001   1.50 (1.35--1.67)
  Amoxicillin/clavulanate   9178                  1139 (12.4)        1491   310 (20.8)    ≤0.001   1.85 (1.61--2.13)
  Cefalexin                 10139                 892 (8.8)          1643   321 (19.5)    ≤0.001   2.52 (2.19--2.90)
  Ciprofloxacin             10137                 1038 (10.2)        1649   374 (22.7)    ≤0.001   2.57 (2.25--2.93)
  Gentamicin                10149                 525 (5.2)          1655   214 (12.9)    ≤0.001   2.72 (2.30--3.22)
  Nitrofurantoin            10134                 551 (5.4)          1647   142 (8.6)     ≤0.001   1.64 (1.35--1.99)
  Trimethoprim              10138                 3989 (39.3)        1652   748 (45.3)    ≤0.001   1.28 (1.15--1.42)
  Cefpodoxime               8512                  525 (6.2)          1418   215 (15.2)    ≤0.001   2.72 (2.29--3.22)

###### 

Frequency of antibiotic susceptibility in relation to age

  Antibiotic                \< 16 years   ≥ 16 years   *P*     OR (CI95%)             
  ------------------------- ------------- ------------ ------- ------------- -------- -------------------
  Ampicillin                1225          763 (62.3)   10484   5694 (54.3)   ≤0.001   0.72 (0.64--0.81)
  Amoxicillin/clavulanate   1109          143 (12.9)   9480    1296 (13.7)   NS       1.07 (0.89--1.29)
  Cefalexin                 1225          100 (8.2)    10462   1104 (10.6)   ≤0.01    1.33 (1.07--1.64)
  Ciprofloxacin             1224          72 (5.9)     10468   1334 (12.7)   ≤0.001   2.34 (1.83--2.99)
  Gentamicin                1226          44 (3.6)     10482   693 (6.6)     ≤0.001   1.90 (1.39--2.59)
  Nitrofurantoin            1224          46 (3.8)     10462   643 (6.1)     ≤0.001   1.68 (1.24--2.28)
  Trimethoprim              1223          566 (46.3)   10471   4129 (39.4)   ≤0.001   0.76 (0.67--0.85)
  Cefpodoxime               1064          43 (4.0)     8787    691 (7.9)     ≤0.001   2.03 (1.48--2.78)

###### 

Frequency of antibiotic susceptibility among community and nosocomial isolates

  Antibiotic                Community   Nosocomial    *P*    OR (CI95%)            
  ------------------------- ----------- ------------- ------ ------------ -------- -------------------
  Ampicillin                10509       5663 (53.9)   1339   870 (65.0)   ≤0.001   1.59 (1.41--1.79)
  Amoxicillin/clavulanate   9564        1145 (12.0)   1145   307 (26.8)   ≤0.001   2.69 (2.33--3.11)
  Cefalexin                 10498       876 (8.3)     1327   340 (25.6)   ≤0.001   3.78 (3.29--4.36)
  Ciprofloxacin             10488       974 (9.3)     1341   441 (32.9)   ≤0.001   4.79 (4.20--5.46)
  Gentamicin                10505       482 (4.6)     1342   260 (19.4)   ≤0.001   5.00 (4.24--5.88)
  Nitrofurantoin            10492       556 (5.3)     1332   139 (10.4)   ≤0.001   2.08 (1.71--2.53)
  Trimethoprim              10492       4103 (39.1)   1341   649 (48.4)   ≤0.001   1.46 (1.30--1.64)
  Cefpodoxime               8868        504 (5.7)     1103   238 (21.6)   ≤0.001   4.57 (3.85--5.41)

Isolates from men were significantly more resistant to all eight agents than isolates from women (Table [1](#T1){ref-type="table"}). In particular, resistance to cefpodoxime, gentamicin, ciprofloxacin and cefalexin was observed more than twice as frequently in isolates from men (odds ratios = 2.5). A significant difference between paediatric and adult isolates was seen for all agents except amoxicillin/clavulanate. Resistance to cefalexin, ciprofloxacin, gentamicin, nitrofurantoin and cefpodoxime was more common in adults whilst ampicillin (OR 0.72) and trimethoprim (OR 0.76) resistance was associated with paediatric strains (Table [2](#T2){ref-type="table"}).

Nosocomial isolates were more resistant than community isolates to all agents tested. The prevalence of gentamicin (OR 4.93), ciprofloxacin (OR 4.74), and cefpodoxime (OR 4.48) resistance exhibited the most marked differences (Table [3](#T3){ref-type="table"}). Patterns of multi-drug resistance are shown in table [4](#T4){ref-type="table"}. Ampicillin resistance in combination with trimethoprim resistance was more frequently observed than resistance to the single agent alone, the combination of ampicillin and trimethoprim resistance was also seen in combination with amoxicillin/clavulanate and ciprofloxacin. Resistance to all agents except nitrofurantoin was the most common multi-drug resistant phenotype and was observed in 1.3% of isolates.

###### 

Distribution of ten most frequently observed antibiotic resistance patterns.

  Antibiotic                          *n*       (%)
  ----------------------------------- --------- -------
  Susceptible                         4290      36.13
  AMP, TRI                            2180      18.36
  AMP                                 1835      15.46
  TRI                                 691       5.82
  AMP, AMC, TRI                       292       2.46
  AMP, AMC                            265       2.23
  AMP, CIP, TRI                       241       2.03
  AMP, AMC, LEX, CIP, GEN, TRI, CPD   164       1.38
  AMP, AMC, LEX, CIP, TRI, CPD        98        0.83
  AMP, NIT, TRI                       95        0.80
  Other                               1722      14.50
  *Total*                             *10151*   *100*

AMP; ampicillin, TRI; trimethoprim, AMC; amoxicillin/clavulanate, CIP; ciprofloxacin, LEX; cefalexin, GEN; gentamicin, CPD; cefpodoxime, NIT; nitrofurantoin

Discussion
==========

In the UK most uncomplicated urinary tract infections are treated in the community with short courses of empirical antibiotics. This relies on susceptibility data from local surveillance schemes as in many cases urine samples are only sent for microbiological evaluation following treatment failure, recurrent or relapsing infection. Although the levels of resistance we observed amongst community isolates may therefore overestimate the true rate of resistance in the community, the high levels of resistance to ampicillin and trimethoprim raise concerns over the use of these agents. This was particularly evident amongst isolates from children, which were more likely to exhibit resistance to ampicillin and trimethoprim compared to those from adults. Increased resistance to the other agents in adults is likely to reflect their wider use both empirically and as second line therapies in relapsing, complicated or nosocomial infection. The higher rates of resistance to all agents observed in males are likely to reflect the complicated nature of UTI in men \[[@B6]\]. Infection in this group usually occurs in the setting of underlying anatomical or functional abnormalities or following instrumentation of the urinary tract and the use of prophylactic antimicrobials. Data on resistance rates in *E. coli*collected at another London teaching hospital from 1995 -- 2000 reveal year on year increases in resistance to amoxicillin, cefuroxime, gentamicin and ciprofloxacin \[[@B7]\]. Resistance to comparable agents in 2005 shows marked elevations in resistance to gentamicin (6.3% v 3.2%) and in particular ciprofloxacin (12% v 1.9%). Resistance to cefpodoxime, which may signify ESBL production \[[@B8]\] was seen in 7.4% of isolates overall, often in combination with resistance to quinolones, aminoglycosides and trimethoprim. Although cefpodoxime resistance was more typical of nosocomial isolates, significant resistance was also observed in the community. These isolates most likely represent CTX-M producing strains of *E. coli*which have disseminated widely throughout Europe post 2000 \[[@B9]\] with those producing CTX-M-15 being most widespread in the UK \[[@B10]\].

Conclusion
==========

Nitrofurantoin remained the most active agent and as it can be administered orally and is highly concentrated in urine, it may therfore be the most appropriate agent for empirical use in uncomplicated UTI. Empirical treatment for nosocomial UTI or infection with multi-drug resistant isolates remains challenging with many authorities recommending parenteral carbapenems (imipenem, ertapenem or meropenem) \[[@B11]\] especially where ESBL producing isolates may be involved. The increasing rates of resistance to uropathogenic *E. coli*isolates reported worldwide \[[@B12],[@B13]\] warrants evaluation of other treatments such as fosfomycin \[[@B14]\] or possibly novel cephalosporin/inhibitor combinations \[[@B15]\].
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